Literature DB >> 25679064

Low frequency of EGFR mutations in pleural mesothelioma patients, Cologne, Germany.

Verena Schildgen1, Olga Pabst, Ramona-Liza Tillmann, Jessica Lüsebrink, Oliver Schildgen, Corinna Ludwig, Michael Brockmann, Erich Stoelben.   

Abstract

EGFR mutations were previously found in patients suffering from peritoneal mesothelioma but have not yet been described in pleural mesothelioma. The aim of the present study was the identification of EGFR mutations in patients suffering from pleural mesothelioma. Pleural mesothelioma tissue from 31 patients was used to analyze possible mutations in the EGFR gene comprising the exons 18-21 with the codons 719, 768, 790, 858+861, 731+734, 785, 797+801, 831, and 868 with pyrosequencing. The results indicate that 31 pleural mesothelioma patients show a wild-type EGFR gene when analyzing the codons D19, 768, 790, 858+861, 731+734, 785, 797+801, 831, and 868, whereas 2 patients have a mutation in the EGFR gene in codon 719. Sanger sequencing of the EGFR codon 785 was used for the determination of a polymorphism in the sequencing of tumor-free patients and pleural mesothelioma patients with a distribution of a wild-type homozygous sequence with guanine, a wild-type heterozygous sequence having guanine and adenine, a wild-type homozygous sequence with adenine, and a wild-type heterozygous sequence with adenine and guanine. Next, the identification of less EGFR mutations in the EGFR gene of the pleural mesothelioma an up to this time unknown polymorphism in the EGFR gene was identified which could be wrongly interpreted as a mutation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25679064     DOI: 10.1097/PDM.0b013e3182a3645e

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  4 in total

1.  Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo.

Authors:  Roberto Bei; Monica Benvenuto; Chiara Focaccetti; Sara Fazi; Marta Moretti; Daniela Nardozi; Valentina Angiolini; Sara Ciuffa; Loredana Cifaldi; Raffaele Carrano; Camilla Palumbo; Martino Tony Miele; Riccardo Bei; Giovanni Barillari; Vittorio Manzari; Enrico De Smaele; Andrea Modesti; Laura Masuelli
Journal:  J Transl Med       Date:  2022-06-25       Impact factor: 8.440

2.  Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.

Authors:  Melike Demir; Halide Kaya; Mahsuk Taylan; Aysun Ekinci; Sureyya Yılmaz; Fatma Teke; Cengizhan Sezgi; Abdullah Cetin Tanrikulu; Fatih Meteroglu; Abdurrahman Senyigit
Journal:  Lung       Date:  2016-03-31       Impact factor: 2.584

3.  Absence of amplification of the FGFR1-gene in human malignant mesothelioma of the pleura: a pilot study.

Authors:  Till Plönes; Frank Beckers; Walburga Engel-Riedel; Erich Stoelben; Michael Brockmann; Verena Schildgen; Oliver Schildgen
Journal:  BMC Res Notes       Date:  2014-08-19

Review 4.  Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP.

Authors:  Gérard Zalcman; Guénaëlle Levallet; Fatéméh Dubois; Céline Bazille; Jérôme Levallet; Elodie Maille; Solenn Brosseau; Jeannick Madelaine; Emmanuel Bergot
Journal:  Target Oncol       Date:  2022-07-30       Impact factor: 4.864

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.